RRML - Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2016): 0.325

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- August 2017 -
 
Involvement of inflammatory marke... 15
Microbial biofilm in human health... 9
CXCL13 levels are more increased ... 7
Biochemical and functional modifi... 7
Therapy-related myelodysplastic s... 7
Severe pneumococcal pneumonia fol... 6
Evaluation of C677T and A1298C po... 6
Association of ischemia-modified ... 6
Markers of cognitive impairment i... 5
IL-6 gene polymorphisms and sepsi... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 25(2)/2017 DOI:10.1515/rrlm-2017-0013
XML
TXT

Case report

Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review

Mihaela Cîrstea, Adriana Coliță, Bogdan Ionescu, Alexandra Ghiaur, Didona Vasilescu, Camelia Dobrea, Cerasela Jardan, Mihaela Dragomir, Anca Gheorghe, Zsofia Várady, Anca Roxana Lupu, Daniel Coriu

Correspondence should be addressed to: Mihaela Cîrstea

Abstract

In the 2016 revision of the World Health Organization classification the term therapy-related myeloid neoplasia (t-MN) defines a subgroup of acute myeloid leukemia (AML) comprising patients who develop myelodysplastic syndrome (MDS-t) or acute myeloid leukemia (AML-t) after treatment with cytotoxic and/or radiation therapy for various malignancies or autoimmune disorders. We report the case of a 36 year old patient with t-MN (t-MDS) after achieving complete remission (CR) of a PML-RARA positive acute promyelocytic leukemia (APL) at 32 months after diagnosis. Initially classified as low risk APL and treated according to the AIDA protocol - induction and 3 consolidation cycles - the patient achieved a complete molecular response in September 2013 and started maintenance therapy. On follow-up PML-RARA transcript remained negative. In January 2016 leukopenia and thrombocytopenia developed and a peripheral blood smear revealed hypogranular and agranular neutrophils. Immunophenotyping in the bone marrow aspirate identified undifferentiated blast cells that did not express cytoplasmic myeloperoxidase. The cytogenetic study showed normal karyotype. The molecular biology tests not identified PML-RARA transcript. A diagnosis of t-MDS (AREB-2 - WHO 2008) was established. Treatment of AML was started with 2 “3+7” regimens and 1 MEC cycle. Two months from diagnosis, while in CR, an allogeneic HSCT from an unrelated HLA compatible donor was performed after myeloablative regimen. An unfavorable clinical evolution was followed by death on day 9 after transplantation. The occurrence of t-MNs during CR of APL represents a particular problem in terms of follow-up and differential diagnosis of relapse and constitutes a dramatic complication for a disease with a favorable prognosis. This work was supported by the grants PN 41-087 /PN2-099 from the Romanian Ministry of Research and Technology.

Keywords: acute promyelocytic leukemia, therapy-related myeloid neoplasms, allogeneic hematopoietic stem cell transplantation

Received: 19.1.2017
Accepted: 18.3.2017
Published: 3.4.2017

 
  PDF Download full text PDF
(714 KB)
     
 
How to cite
Cîrstea M, Coliță A, Ionescu B, Ghiaur A, Vasilescu D, Dobrea C, et al. Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review. Rev Romana Med Lab. 2017;25(2):165-79. DOI:10.1515/rrlm-2017-0013